Edition:
India

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

38.80USD
18 Oct 2019
Change (% chg)

$-1.71 (-4.22%)
Prev Close
$40.51
Open
$40.22
Day's High
$40.65
Day's Low
$38.61
Volume
265,718
Avg. Vol
225,969
52-wk High
$61.20
52-wk Low
$33.51

Latest Key Developments (Source: Significant Developments)

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Fibrogen Inc::FIBROGEN-JAPAN'S MINISTRY OF HEALTH,LABOUR AND WELFARE APPROVED EVRENZO FOR TREATMENT OF ANEMIA RELATED TO CHRONIC KIDNEY DISEASE IN DIALYSIS PATIENTS.  Full Article

FibroGen Reports Q2 Earnings Per Share $1.26
Friday, 9 Aug 2019 

Aug 8 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $1.26.Q2 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.Q2 REVENUE $180 MILLION.Q2 REVENUE ESTIMATE $29 MILLION -- REFINITIV IBES DATA.ON TRACK TO SUBMIT U.S. NDA FOR ROXADUSTAT IN OCTOBER.AT JUNE 30 HAD $686.1 MILLION IN CASH, RESTRICTED TIME DEPOSITS, CASH EQUIVALENTS, INVESTMENTS, AND RECEIVABLES.  Full Article

FibroGen Q1 Loss Per Share $0.53
Friday, 10 May 2019 

May 9 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.53.Q1 EARNINGS PER SHARE ESTIMATE $-0.67 -- REFINITIV IBES DATA.  Full Article

Fibrogen Inc - Co and Astellas Pharma Inc entered into an amendment to collaboration agreement - SEC Filing
Saturday, 8 Dec 2018 

Dec 7 (Reuters) - Astellas Pharma Inc <4503.T>::FIBROGEN INC SAYS ON NOV 30, CO AND ASTELLAS PHARMA INC. ENTERED INTO AN AMENDMENT TO COLLABORATION AGREEMENT DATED AS OF JUNE 1, 2005 - SEC FILING.FIBROGEN INC - UNDER THIS AMENDMENT, FIBROGEN WOULD CONTINUE TO MANUFACTURE AND DELIVER TO ASTELLAS ROXADUSTAT ACTIVE PHARMACEUTICAL INGREDIENT.FIBROGEN INC - AMENDMENT OBLIGATES ASTELLAS TO PURCHASE A TOTAL OF NET $62.7 MILLION OF ROXADUSTAT ACTIVE PHARMACEUTICAL INGREDIENT.  Full Article

Fibrogen Q3 Loss Per Share $0.50
Friday, 9 Nov 2018 

FibroGen Inc ::FIBROGEN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.PHASE 3 CLINICAL TRIALS IN IPF AND PANCREATIC CANCER TO INITIATE IN Q1 2019.QTRLY TOTAL REVENUE $29 MILLION VERSUS $40.6 MILLION.  Full Article

Fibrogen Q2 Loss Per Share $0.28
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $43.95 MILLION VERSUS $30.27 MILLION.Q2 REVENUE VIEW $27.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment
Friday, 2 Mar 2018 

March 1 (Reuters) - FibroGen Inc ::UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER.FIBROGEN - FAST TRACK DESIGNATION FOLLOWS REVIEW OF CO'S PHASE 2 CLINICAL TRIAL EVALUATING PAMREVLUMAB IN COMBINATION WITH GEMCITABINE & NAB-PACLITAXEL.  Full Article

Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients
Thursday, 1 Mar 2018 

March 1 (Reuters) - Fibrogen Inc ::FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER.  Full Article

FibroGen Q4 Loss Per Share $0.27
Wednesday, 28 Feb 2018 

Feb 27 (Reuters) - Fibrogen Inc ::FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.27.QTRLY ‍TOTAL REVENUE OF $42.5 MILLION VERSUS $31.9 MILLION.  Full Article

Fibrogen Inc reports Q3 loss per share $0.50
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article